Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 Mar;56(3):632–639. doi: 10.1128/iai.56.3.632-639.1988

Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains.

N L Schiller 1
PMCID: PMC259338  PMID: 3125110

Abstract

The mechanism of complement-mediated killing of seven serum-sensitive Pseudomonas aeruginosa strains was examined. All seven strains were sensitive to the bactericidal activity of 20% pooled normal human serum (PNHS) containing magnesium EGTA, which blocks the classical complement pathway (CCP), or 20% PNHS preheated to 50 degrees C for 20 min, which inactivates the alternative complement pathway, suggesting that either pathway was effective against these strains. However, for four of these strains, optimal killing required the function of both pathways. Preabsorption of PNHS with serum-sensitive strains dramatically reduced the killing activity of serum for the homologous strains when a concentration of 10% serum was used, implying a role for antibody in the activation of complement via the CCP. Affinity purification of antibodies to the rough lipopolysaccharide (LPS) on strain 144M resulted in a pool of antibodies which could restore all of the bactericidal activity and most of the C3 activation-deposition activity of serum which had been lost by preabsorption with 144M. Confirmation that the LPS was the target for these bactericidal antibodies was provided by demonstrating that exogenously added 144M LPS inhibited the killing activity of PNHS. These anti-144M LPS-specific antibodies were also bactericidal for the six other serum-sensitive strains examined, suggesting that all seven strains shared an antigenic determinant recognized by these anti-144M LPS-specific antibodies. Results from cross-absorption studies imply that there are bactericidal antibodies in PNHS directed to additional bacterial targets. These studies suggest that part of the bactericidal activity of PNHS is due to binding of antibodies to the rough LPS on serum-sensitive strains, initiating activation of the CCP, and that all seven strains examined shared this bactericidal antibody-binding site.

Full text

PDF
632

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen R. J., Scott G. K. Comparison of the effects of different lipopolysaccharides on the serum bactericidal reactions of two strains of Escherichia coli. Infect Immun. 1981 Feb;31(2):831–832. doi: 10.1128/iai.31.2.831-832.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allen R. J., Scott G. K. The effect of purified lipopolysaccharide on the bactericidal reaction of human serum complement. J Gen Microbiol. 1980 Mar;117(1):65–72. doi: 10.1099/00221287-117-1-65. [DOI] [PubMed] [Google Scholar]
  3. Apicella M. A., Westerink M. A., Morse S. A., Schneider H., Rice P. A., Griffiss J. M. Bactericidal antibody response of normal human serum to the lipooligosaccharide of Neisseria gonorrhoeae. J Infect Dis. 1986 Mar;153(3):520–526. doi: 10.1093/infdis/153.3.520. [DOI] [PubMed] [Google Scholar]
  4. Bodey G. P., Bolivar R., Fainstein V., Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis. 1983 Mar-Apr;5(2):279–313. doi: 10.1093/clinids/5.2.279. [DOI] [PubMed] [Google Scholar]
  5. Clas F., Loos M. Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun. 1981 Mar;31(3):1138–1144. doi: 10.1128/iai.31.3.1138-1144.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clas F., Schmidt G., Loos M. The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol. 1985;121:19–72. doi: 10.1007/978-3-642-45604-6_3. [DOI] [PubMed] [Google Scholar]
  7. Coonrod J. D., Jenkins S. D. Evaluation of a hemolytic assay of the alternative complement pathway in human serum. Am J Clin Pathol. 1980 Aug;74(2):167–173. doi: 10.1093/ajcp/74.2.167. [DOI] [PubMed] [Google Scholar]
  8. Dahlberg-Lagergård T. Target antigens for bactericidal and opsonizing antibodies to Haemophilus influenzae. Acta Pathol Microbiol Immunol Scand C. 1982 Aug;90(4):209–216. doi: 10.1111/j.1699-0463.1982.tb01440.x. [DOI] [PubMed] [Google Scholar]
  9. Darveau R. P., Hancock R. E. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol. 1983 Aug;155(2):831–838. doi: 10.1128/jb.155.2.831-838.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eidinger D., Bello E., Mates A. The heterocytotoxicity of human serum. I. Activation of the alternative complement pathway by heterologous target cells. Cell Immunol. 1977 Mar 1;29(1):174–186. doi: 10.1016/0008-8749(77)90286-6. [DOI] [PubMed] [Google Scholar]
  11. Fetterhoff T. J., McCarthy R. C. A micromodification of the CH50 test for the classical pathway of complement. J Clin Lab Immunol. 1984 Aug;14(4):205–208. [PubMed] [Google Scholar]
  12. Fick R. B., Jr, Naegel G. P., Reynolds H. Y. Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies. J Immunol Methods. 1980;38(1-2):103–116. doi: 10.1016/0022-1759(80)90335-x. [DOI] [PubMed] [Google Scholar]
  13. Fine D. P. Comparison of ethyleneglycoltetraacetic acid and its magnesium salt as reagents for studying alternative complement pathway function. Infect Immun. 1977 Apr;16(1):124–128. doi: 10.1128/iai.16.1.124-128.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Glynn A. A., Ward M. E. Nature and Heterogeneity of the Antigens of Neisseria gonorrhoeae Involved in the Serum Bactericidal Reaction. Infect Immun. 1970 Aug;2(2):162–168. doi: 10.1128/iai.2.2.162-168.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldman J. N., Ruddy S., Austen K. F., Feingold D. S. The serum bactericidal reaction. 3. Antibody and complement requirements for killing a rough Escherichia coli. J Immunol. 1969 Jun;102(6):1379–1387. [PubMed] [Google Scholar]
  16. Goldman R. C., Joiner K., Leive L. Serum-resistant mutants of Escherichia coli O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen. J Bacteriol. 1984 Sep;159(3):877–882. doi: 10.1128/jb.159.3.877-882.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hancock R. E., Mutharia L. M., Chan L., Darveau R. P., Speert D. P., Pier G. B. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun. 1983 Oct;42(1):170–177. doi: 10.1128/iai.42.1.170-177.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Inoue K., Yonemasu K., Takamizawa A., Amano T. [Studies on the immune bacteriolysis. XIV. Requirement of all nine components of complement for immune bacteriolysis]. Biken J. 1968 Sep;11(3):203–206. [PubMed] [Google Scholar]
  19. Joiner K. A., Hammer C. H., Brown E. J., Cole R. J., Frank M. M. Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death. J Exp Med. 1982 Mar 1;155(3):797–808. doi: 10.1084/jem.155.3.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Joiner K. A., Hammer C. H., Brown E. J., Frank M. M. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane. J Exp Med. 1982 Mar 1;155(3):809–819. doi: 10.1084/jem.155.3.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Joiner K. A., Schmetz M. A., Goldman R. C., Leive L., Frank M. M. Mechanism of bacterial resistance to complement-mediated killing: inserted C5b-9 correlates with killing for Escherichia coli O111B4 varying in O-antigen capsule and O-polysaccharide coverage of lipid A core oligosaccharide. Infect Immun. 1984 Jul;45(1):113–117. doi: 10.1128/iai.45.1.113-117.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Meshulam T., Verbrugh H., Verhoef J. Serum-induced lysis of Pseudomonas aeruginosa. Eur J Clin Microbiol. 1982 Feb;1(1):1–6. doi: 10.1007/BF02014132. [DOI] [PubMed] [Google Scholar]
  23. Morrison D. C., Kline L. F. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol. 1977 Jan;118(1):362–368. [PubMed] [Google Scholar]
  24. Mutharia L. M., Hancock R. E. Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies. Infect Immun. 1983 Dec;42(3):1027–1033. doi: 10.1128/iai.42.3.1027-1033.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Odumeru J. A., Wiseman G. M., Ronald A. R. Role of lipopolysaccharide and complement in susceptibility of Haemophilus ducreyi to human serum. Infect Immun. 1985 Nov;50(2):495–499. doi: 10.1128/iai.50.2.495-499.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Offredo-Hemmer C., Berche P., Véron M. A complement-sensitive mutant of Pseudomonas aeruginosa. Ann Microbiol (Paris) 1983 May-Jun;134A(3):281–294. [PubMed] [Google Scholar]
  27. Penketh A., Pitt T., Roberts D., Hodson M. E., Batten J. C. The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis. Am Rev Respir Dis. 1983 May;127(5):605–608. doi: 10.1164/arrd.1983.127.5.605. [DOI] [PubMed] [Google Scholar]
  28. Pier G. B., Ames P. Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement. J Infect Dis. 1984 Aug;150(2):223–228. doi: 10.1093/infdis/150.2.223. [DOI] [PubMed] [Google Scholar]
  29. Reyes M. P., El-Khatib M. R., Brown W. J., Smith F., Lerner A. M. Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis. 1979 Aug;140(2):192–202. doi: 10.1093/infdis/140.2.192. [DOI] [PubMed] [Google Scholar]
  30. Rowley D. Antibacterial action of antibody and complement. J Infect Dis. 1973 Jul;128(Suppl):170–175. doi: 10.1093/infdis/128.supplement_1.s170. [DOI] [PubMed] [Google Scholar]
  31. Sansano M., Jr, Reynard A. M., Cunningham R. K. Inhibition of serum bactericidal reaction by lipopolysaccharide. Infect Immun. 1985 Jun;48(3):759–762. doi: 10.1128/iai.48.3.759-762.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schiller N. L., Alazard M. J., Borowski R. S. Serum sensitivity of a Pseudomonas aeruginosa mucoid strain. Infect Immun. 1984 Sep;45(3):748–755. doi: 10.1128/iai.45.3.748-755.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schiller N. L., Hatch R. A. The serum sensitivity, colonial morphology, serogroup specificity, and outer membrane protein of Pseudomonas aeruginosa strains isolated from several clinical sites. Diagn Microbiol Infect Dis. 1983 Jun;1(2):145–157. doi: 10.1016/0732-8893(83)90044-5. [DOI] [PubMed] [Google Scholar]
  34. Schiller N. L., Joiner K. A. Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun. 1986 Dec;54(3):689–694. doi: 10.1128/iai.54.3.689-694.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Schreiber R. D., Morrison D. C., Podack E. R., Müller-Eberhard H. J. Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med. 1979 Apr 1;149(4):870–882. doi: 10.1084/jem.149.4.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Shafer W. M., Joiner K., Guymon L. F., Cohen M. S., Sparling P. F. Serum sensitivity of Neisseria gonorrhoeae: the role of lipopolysaccharide. J Infect Dis. 1984 Feb;149(2):175–183. doi: 10.1093/infdis/149.2.175. [DOI] [PubMed] [Google Scholar]
  37. Taylor P. W. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev. 1983 Mar;47(1):46–83. doi: 10.1128/mr.47.1.46-83.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Taylor P. W., Kroll H. P. Interaction of human complement proteins with serum-sensitive and serum-resistant strains of Escherichia coli. Mol Immunol. 1984 Jul;21(7):609–620. doi: 10.1016/0161-5890(84)90046-4. [DOI] [PubMed] [Google Scholar]
  39. Thomassen M. J., Demko C. A. Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients. Infect Immun. 1981 Aug;33(2):512–518. doi: 10.1128/iai.33.2.512-518.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Young L. S., Armstrong D. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972 Sep;126(3):257–276. doi: 10.1093/infdis/126.3.257. [DOI] [PubMed] [Google Scholar]
  41. van der Ley P., Kuipers O., Tommassen J., Lugtenberg B. O-antigenic chains of lipopolysaccharide prevent binding of antibody molecules to an outer membrane pore protein in Enterobacteriaceae. Microb Pathog. 1986 Feb;1(1):43–49. doi: 10.1016/0882-4010(86)90030-6. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES